Andrew is chief scientific officer at Chinook Therapeutics, overseeing the discovery research, non-clinical development and translational medicine teams. Andrew joined Chinook in May 2019 as head of renal discovery and translational medicine. Prior to joining Chinook, Andrew was senior director of discovery and translational biology at Ardelyx, where he and his teams played key roles in delivering small molecule candidates for the treatment of cardio-renal diseases, as well as elucidating the novel molecular mechanism of action of tenapanor, currently under NDA review by the FDA for the treatment of hyperphosphatemia in dialysis patients. Previously, Andrew spent over seven years at AbbVie in roles of increasing responsibility and led the renal discovery scientific strategy to treat chronic kidney disease. Andrew received his Ph.D. in pharmacology from Michigan State University and completed training in Veterinary Medicine and Surgery at Murdoch University in Australia.
Current role